false
0001728328
A1
0001728328
2025-10-09
2025-10-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 9, 2025
INMED PHARMACEUTICALS
INC.
(Exact Name of Company as Specified in Charter)
| British Columbia |
|
001-39685 |
|
98-1428279 |
|
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
InMed Pharmaceuticals Inc.
Suite 1445 - 885 W. Georgia Street,
Vancouver, B.C.
Canada |
|
V6C 3E8 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
Company’s telephone number, including
area code: (604) 669-7207
Not applicable
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
| ☐ | Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange
on which registered |
| Common Shares, no par value |
|
INM |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On October 7, 2025, the board of directors (the
“Board”) of InMed Pharmaceuticals Inc. (the “Company”) appointed Mr. Neil Klompas as a director and concurrently
increased the size of the Board to five members, both effective as of October 9, 2025. Mr. Klompas may be appointed to one or more of
the committees of the Board, but the appointments have not been determined at this time. Mr. Klompas’s term as a member of the Board
will expire immediately before the Annual General Meeting to be held in 2025.
There are no arrangements nor understandings between
Mr. Klompas, on the one hand, and the Company or any other persons, on the other hand, pursuant to which he was selected as a director
of the Company. There are no related party transactions between the Company and Mr. Klompas (or any of his immediate family members) requiring
disclosure under Item 404(a) of Regulation S-K. Mr. Klompas does not have any family relationship with any of the Company’s other
directors or executive officers.
Mr. Klompas will be entitled to receive compensation
for service as a non-employee director consistent with the Company’s non-employee director compensation program, which includes
an annual retainer of US50,000 and may include additional amounts for serving as a Board committee member, if applicable. In connection
with his appointment to the Board, Mr, Klompas executed the Company’s standard form of indemnification agreement for directors.
Item 7.01 Regulation FD Disclosure.
On October 9, 2025, the Company issued a press
release announcing the appointment of Mr. Neil Klompas as a director. A copy of the press release is furnished as Exhibit 99.1 hereto
and is incorporated herein by reference.
The information set forth in this Item 7.01, including
Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth
in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
The following exhibits shall be deemed to be furnished, and not filed:
Exhibit
No. |
|
Description |
| 99.1 |
|
Press Release filed October 9, 2025 |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
INMED PHARMACEUTICALS INC. |
| |
|
|
| Date: October 10, 2025 |
By: |
/s/ Eric A. Adams |
| |
|
Eric A. Adams |
| |
|
President and CEO |
2
